Supriya Lifescience Limited filed a petition before the Hon'ble Supreme Court of India on October 8, 2026. This legal move challenges an earlier order issued by the High Court regarding ongoing judicial proceedings involving the company.

The filing serves as a further update to the stock exchanges under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It follows the company's previous intimation on September 23, 2026, which detailed the receipt of the High Court's order.

Legal status and company stance

The matter is currently sub judice and pending consideration before the Supreme Court. Given the active legal proceedings, Supriya Lifescience stated it does not wish to comment further on the merits or potential outcome of the case at this stage.

The company confirmed it will continue to monitor the situation closely. It committed to keeping the stock exchanges and shareholders informed of any material developments as and when updates are received from the court or through other channels in accordance with applicable laws.

Procedural timeline

The progression of this legal dispute highlights the company's strategy to escalate matters beyond the High Court level.

The disclosure was signed by Prachi Sathe, Company Secretary and Compliance Officer, ensuring compliance with regulatory reporting standards for listed entities.

Supriya Lifescience Limited concluded its 18th Annual General Meeting on September 24, 2026, with all five ordinary resolutions passed with requisite majority. The meeting, held via video conferencing, approved the audited financial statements for FY26 and a final dividend of ₹1.00 per equity share.

The proceedings commenced at 3:00 pm and concluded at 3:50 pm. Dr. Satish Wagh, Chairman and Executive Director, was unable to chair the meeting due to a medical emergency. Ms. Shivani Wagh, Joint Managing Director, assumed the chair after ascertaining the quorum.

Key resolutions approved

Shareholders voted on five key items of business, all classified as ordinary resolutions:

• Adoption of audited financial statements for FY26
• Declaration of final dividend of ₹1.00 per share (50% on face value of ₹2)
• Reappointment of Dr. Saloni Wagh (DIN: 08491410) retiring by rotation
• Ratification of cost auditor remuneration for FY27
• Reappointment of Ms. Shivani Wagh (DIN: 08491420) retiring by rotation

Voting participation details

The voting results highlight significant promoter support across all resolutions. Public institutional shareholders showed notable dissent in specific director reappointments, particularly for Dr. Saloni Wagh.

What the numbers show

A divergence in voting patterns emerged during the reappointment of Dr. Saloni Wagh. While promoters voted unanimously in favor, public institutions cast 136,499 votes against her reappointment, representing 4.13% of the votes polled by that category. This contrasts sharply with the near-unanimous support for the dividend declaration and financial statement adoption, where dissent from public institutions was zero. This suggests specific concerns among institutional investors regarding this particular director appointment, distinct from their broader approval of company performance metrics.